{
    "ticker": "XTL",
    "name": "XTL Biopharmaceuticals Ltd.",
    "description": "XTL Biopharmaceuticals Ltd. is a biopharmaceutical company focused on developing innovative therapies for serious medical conditions. Established in 2008, XTL is committed to advancing treatments in the fields of autoimmune diseases and other chronic conditions through its proprietary technologies. The company\u2019s lead product candidate, XTL-6865, is a novel biologic therapy targeting autoimmune diseases, specifically focusing on the treatment of IgA nephropathy, a rare kidney disorder. XTL is also exploring other indications, leveraging its expertise in immunology and protein engineering. The company is headquartered in Rehovot, Israel, and operates with a robust pipeline designed to address unmet medical needs. With a dedicated team of scientists and researchers, XTL aims to bring forth safe and effective therapies to improve patient outcomes globally. The organization is actively engaged in clinical trials and collaborations with academic institutions to validate its therapeutic approaches and expand its portfolio. XTL Biopharmaceuticals is driven by a commitment to scientific excellence and patient welfare, striving to be a leader in the biopharmaceuticals industry through innovative research and development.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Rehovot, Israel",
    "founded": "2008",
    "website": "https://www.xtlbio.com",
    "ceo": "Dr. Eliav Barr",
    "social_media": {
        "twitter": "https://twitter.com/XTLBiopharma",
        "linkedin": "https://www.linkedin.com/company/xtl-biopharmaceuticals-ltd"
    },
    "investor_relations": "https://www.xtlbio.com/investor-relations",
    "key_executives": [
        {
            "name": "Dr. Eliav Barr",
            "position": "CEO"
        },
        {
            "name": "Dr. Yona Shtern",
            "position": "Chairman"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "XTL-6865"
            ]
        }
    ],
    "seo": {
        "meta_title": "XTL Biopharmaceuticals Ltd. | Innovative Therapies in Biopharmaceuticals",
        "meta_description": "Learn about XTL Biopharmaceuticals Ltd., a leading biopharmaceutical company focused on developing innovative therapies for autoimmune diseases and other serious medical conditions.",
        "keywords": [
            "XTL Biopharmaceuticals",
            "Biopharmaceuticals",
            "Autoimmune Diseases",
            "IgA Nephropathy",
            "Novel Therapies"
        ]
    },
    "faq": [
        {
            "question": "What is XTL Biopharmaceuticals known for?",
            "answer": "XTL Biopharmaceuticals is known for developing innovative therapies for autoimmune diseases, particularly its lead product candidate XTL-6865."
        },
        {
            "question": "Who is the CEO of XTL Biopharmaceuticals?",
            "answer": "Dr. Eliav Barr is the CEO of XTL Biopharmaceuticals Ltd."
        },
        {
            "question": "Where is XTL Biopharmaceuticals headquartered?",
            "answer": "XTL Biopharmaceuticals is headquartered in Rehovot, Israel."
        },
        {
            "question": "What are XTL Biopharmaceuticals' main products?",
            "answer": "XTL Biopharmaceuticals' main product candidate is XTL-6865, targeting autoimmune diseases."
        },
        {
            "question": "When was XTL Biopharmaceuticals founded?",
            "answer": "XTL Biopharmaceuticals was founded in 2008."
        }
    ],
    "competitors": [
        "AMGN",
        "BIIB",
        "GILD",
        "REGN"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRK",
        "ABBV"
    ]
}